Ventures Iii, Llc Versant V... Net Worth

The estimated Net Worth of Ventures Iii, Llc Versant V... is at least $191 Tisíc dollars as of 8 June 2016. Ventures V owns over 714,285 units of Flexion Therapeutics Inc stock worth over $190,591 and over the last 8 years Ventures sold FLXN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ventures V FLXN stock SEC Form 4 insiders trading

Ventures has made over 2 trades of the Flexion Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Ventures bought 714,285 units of FLXN stock worth $9,999,990 on 8 June 2016.

The largest trade Ventures's ever made was buying 714,285 units of Flexion Therapeutics Inc stock on 8 June 2016 worth over $9,999,990. On average, Ventures trades about 714,285 units every 0 days since 2016. As of 8 June 2016 Ventures still owns at least 20,739 units of Flexion Therapeutics Inc stock.

You can see the complete history of Ventures V stock trades at the bottom of the page.

What's Ventures V's mailing address?

Ventures's mailing address filed with the SEC is 1 Sansome St # 2000, San Francisco, CA 94104, USA.

Insiders trading at Flexion Therapeutics Inc

Over the last 11 years, insiders at Flexion Therapeutics Inc have traded over $7,066,621 worth of Flexion Therapeutics Inc stock and bought 7,091,809 units worth $98,920,816 . The most active insiders traders include Holdings A/S Novo, Bradley J Ph D Bolzon a Samuel D Colella. On average, Flexion Therapeutics Inc executives and independent directors trade stock every 24 days with the average trade being worth of $609,564. The most recent stock trade was executed by Christina Willwerth on 19 July 2021, trading 3,945 units of FLXN stock currently worth $25,445.

What does Flexion Therapeutics Inc do?

Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The Company's core values are focus, ingenuity, tenacity, transparency and fun.

Complete history of Ventures V stock trades at Flexion Therapeutics Inc

Flexion Therapeutics Inc executives and stock owners

Flexion Therapeutics Inc executives and other stock owners filed with the SEC include:

• Michael Clayman,
  President, Chief Executive Officer, Director
• David Arkowitz,
  Chief Financial Officer
• Scott Kelley,
  Chief Medical Officer
• Mark Levine,
  General Counsel and Corporate Secretary
• Dr. Neil Bodick,
  Consultant
• Patrick Mahaffy,
  Independent Chairman of the Board
• Sandesh Mahatme,
  Independent Director
• Samuel Colella,
  Independent Director
• Alan Milinazzo,
  Independent Director
• Mark Stejbach,
  Independent Director
• C. Ann Merrifield,
  Independent Director
• Scott Canute,
  Independent Director
• Heath Lukatch,
  Independent Director
• Scott Young,
  IR Contact Officer
• Elizabeth Kwo,
  Director
• Christina Willwerth,
  Chief Strategy Officer
• Kerry Wentworth,
  Chief Regulatory Officer
• Melissa Layman,
  Chief Commercial Officer
• John Magee,
  VP of Sales
• Carolyn Beaty Scimemi,
  VP, Legal Affairs & Chief Compliance Officer
• David A. Arkowitz M.B.A.,
  Chief Financial Officer
• Ventures Iii, Llc Versant V...,
  
• Yamo Deniz,
  Chief Medical Officer
• Frederick W Driscoll,
  Chief Financial Officer
• Barbara N Bolzon Bradley J ...,
  
• William T. Andrews,
  Chief Medical Officer
• Utpal Koppikar,
  Director
• Neil Bodick,
  Chief Scientific Officer
• Ventures Ii Lp5 Am Co Inves...,
  
• Holdings A/S Novo,
  10% owner
• Partners Sas Sofinnova,
  10% owner
• Venture Capital Iii, L.P.Bo...,
  
• Venture Capital Iii, L.P.Ve...,
  
• Rafael Tordjman,
  Director
• Andrew J. Schwab,
  Director
• Bradley J Ph D Bolzon,
  Director
• Venture Capital Iii, L.P.Ve...,
  
• Inc Pfizer,
  10% owner
• Management, Llc Newtyn,
  10% owner
• Adam Muzikant,
  Chief Business Officer